Clinical trials: Wet Age-related Macular Degeneration
Macular Edema, Macular Degeneration
Study Evaluating Retinal Health Monitoring System Thickness Module
Evaluate the ability and accuracy of the Retinal Health Monitoring System - Retinal Thickness Module (RHMS - RTM).
- Trial name
- NCT04428242
- Testing
- RHMS-RTM, SD-OCT
- Where
- United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- Kubota Vision Inc.
Wet Macular Degeneration
OZURDEX in Age Related Macular Degeneration as Adjunct to Ranibizumab
In the Western World, Age Related Macular Degeneration (ARMD) is a leading cause of blindness. This disease was once thought to be a natural part of aging, but recent research has introduced effective treatments.
- Trial name
- STAR (NCT01243086)
- Testing
- Ranibizumab, OZURDEX
- Where
- Canada
- Volunteers
- 10 people
- Sponsor
- McMaster University
Wet Age-related Macular Degeneration (wAMD)
High Dose (HD) Aflibercept Switch in Neovascular Age-related Macular Degeneration (nAMD): to Load or Maintain (HEIRLOOM)
The purpose of this study is to compare two treatment frequencies using EYLEA® HD (aflibercept 8mg) in patients with wet age-related macular degeneration (wAMD) that are currently treated with EYLEA® (aflibercept 2mg).
- Trial name
- HEIRLOOM (NCT07129239)
- Testing
- Maintenance
- Where
- Canada
- Volunteers
- 180 people
- Sponsor
- Clinique de Retine de l'est
Neovascular (Wet) Age-Related Macular Degeneration
Switch From 2mg Aflibercept to 8mg Aflibercept in Patients With Neovascular Age-related Macular Degeneration
This study will investigate if switching patients who appear to be sub-optimal responders to the current standard of care treatment with Aflibercept 2mg to Aflibercept 8mg will prolong treatment intervals and maintain visual…
- Trial name
- NCT07390253
- Testing
- Aflibercept
- Where
- Austria
- Volunteers
- 50 people
- Sponsor
- Vienna Institute for Research in Ocular Surgery
Macular Degeneration
A Safety and Efficacy Study of MSI-1256F (Squalamine Lactate) To Treat "Wet" Age-Related Macular Degeneration
Age-Related Macular Degeneration (AMD) is a degenerative eye disease of the retina that causes a progressive loss of central vision. AMD is the leading cause of legal blindness among adults age 50 or older in the Western world.
- Trial name
- NCT00089830
- Testing
- MSI-1256F (Squalamine Lactate)
- Where
- United States
- Volunteers
- 120 people
- Sponsor
- Genaera Corporation
Age-Related Macular Degeneration, Macular Degeneration
Repeated Eye Injections of Aflibercept for Treatment of Wet Age Related Macular Degeneration
To evaluate the visual outcome and number of injections required during an optical coherence tomography (OCT)-guided treat and extend regimen with intravitreal aflibercept for treatment of subfoveal neovascular age-related…
- Trial name
- ATLAS (NCT01773954)
- Testing
- Intravitreal Aflibercept Injection
- Where
- 3 sites in United States
- Volunteers
- 40 people
- Sponsor
- MidAtlantic Retina
Diabetic Macular Edema (DME), Neovascular (Wet) Age-Related Macular Degeneration
A Phase 1b Study to Assess the Safety, Tolerability, Pharmacokinetics, and Exploratory Efficacy of Intravitreal OLN324
A Phase 1b Study to Assess the Safety, Tolerability, Pharmacokinetics, and Exploratory Efficacy of Intravitreal OLN324
- Trial name
- JADE (NCT07484074)
- Testing
- Faricimab, OLN324
- Where
- 30 sites in United States, Puerto Rico
- Volunteers
- 164 people
- Sponsor
- Ollin Biosciences, Inc.
Neovascular Age-Related Macular Degeneration
A Depot Formulation of Sunitinib Malate (GB-102) Compared to Aflibercept in Subjects With Wet AMD
Phase 2b, multicenter, visual examiner-masked, randomized active-controlled, parallel-arm design study to evaluate the safety and duration of repeated IVT injections of 3 dose levels of GB-102 compared with aflibercept.
- Trial name
- ALTISSIMO (NCT03953079)
- Testing
- Drug: GB-102, Aflibercept
- Where
- 33 sites in United States
- Volunteers
- 56 people
- Sponsor
- Graybug Vision
Age Related Macular Degeneration
Comparison of Treatment Response to Intravitreal Injection of Combined Propranolol and Bevacizumab Versus Bevacizumab Monotherapy in Patients With Wet Age Related Macular Degeneration :A Clinical Trial
This study is designed to compare the effect of combined intravitreal Bevacizumab and Propranolol injection versus Bevacizumab monotherapy in patients with Age Related Macular Degeneration.
- Trial name
- NCT03609307
- Testing
- Combined Intravitreal bevacizumab and propranolol, Intravitreal bevacizumab
- Where
- Iran
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Shahid Beheshti University of Medical Sciences
Age Related Macular Degeneration (ARMD)
Efficacy, Safety, pharmacokinetiсs, Immunogenicity of GNR-067 and Lucentis®
This is a randomized, double-blind, comparative, parallel group study of the efficacy, safety pharmacokinetics, and immunogenicity of GNR-067 and Lucentis® in patients with neovascular (wet) age-related macular degeneration.
- Trial name
- NAP (NCT04667039)
- Testing
- GNR-067, Lucentis®
- Where
- 9 sites in Russia
- Volunteers
- 408 people
- Sponsor
- AO GENERIUM
Neovascular Wet Age-related Macular Degeneration (AMD)
Phase 1 Safety Study With Intravitreal (IVT) REGN2176-3 in Patients Aged 50 Years and Older With Wet AMD
The primary objective of the study is to investigate the safety of intravitreal (IVT) REGN2176-3 in patients with neovascular wet age-related macular degeneration (AMD).
- Trial name
- NCT02061865
- Testing
- REGN2176-3
- Where
- 4 sites in United States
- Volunteers
- 12 people
- Sponsor
- Regeneron Pharmaceuticals
Exudative Macular Degeneration
Pilot Study of X-82 in Patients With Wet AMD
The objective of this study is to evaluate the safety and preliminary biologic activity/efficacy of X-82 in patients with wet Age-related Macular Degeneration (AMD).
- Trial name
- NCT01674569
- Testing
- X-82 oral, ranibizumab (Lucentis)
- Where
- 5 sites in United States
- Volunteers
- 35 people
- Sponsor
- Tyrogenex
Retinal Disease, Age-Related Macular Degeneration
Stem Cell Ophthalmology Treatment Study II
This study will evaluate the use of autologous bone marrow derived stem cells (BMSC) for the treatment of retinal and optic nerve damage or disease.
- Conditions
- Retinal Disease, Age-Related Macular Degeneration, Retinitis Pigmentosa, Stargardt Disease
- Trial name
- SCOTS2 (NCT03011541)
- Testing
- Arm 1
- Where
- 4 sites in United States, Austria and 1 more
- Volunteers
- 500 people
- Sponsor
- MD Stem Cells
Wet Age-related Macular Degeneration
A Study to Compare JL14002 to Lucentis® in Subjects With Wet Age-related Macular Degeneration (wAMD)
This is a randomised, double-masked, parallel group, multicentre study to evaluate the efficacy and safety of JL14002 compared to Lucentis® in subjects with wAMD.
- Trial name
- NCT07389577
- Testing
- JL14002 monoclonal antibody(Fixed dosing regimen), Ranibizumab(Fixed dosing regimen), JL14002 monoclonal antibody(PRN)
- Where
- China
- Volunteers
- 443 people
- Sponsor
- Jecho Biopharmaceuticals Co., Ltd.
Maculopathy, Maculopathy, Age Related
CRYSTALSIGHT: ''Cohort 1.5" Clinical Investigation Study With OCCUTRACK and Tan Tock Seng Eye Clinic to Further Develop Remote Monitoring of Maculopathy at Home Using Artificial Intelligence for Eye Tracking
The development of a next-generation 'CRYSTALSIGHT' solution using combinations of a novel and cost-effective eye-tracking system with artificial intelligence-based eye-tracking algorithms that detect macular abnormalities and…
- Conditions
- Maculopathy, Maculopathy, Age Related, Macular Degeneration, Age-Related, Diabetic Retinopathy
- Trial name
- NCT07255885
- Testing
- CRYSTALSIGHT Test
- Where
- Singapore
- Volunteers
- 20 people
- Sponsor
- Tan Tock Seng Hospital
Age-related Macular Degeneration
Pilot Study of Lucentis Combined With Proton Beam Irradiation in Treating Wet Age-related Macular Degeneration
Because a possible synergism of radiation and inhibitors of vascular endothelial growth factor has been shown in cancer patients and patients with wet macular degeneration, this pilot study is being conducted to determine whether…
- Trial name
- NCT00517010
- Testing
- Proton beam irradiation and ranibizumab
- Volunteers
- 6 people
- Sponsor
- University of California, Davis
Exudative Macular Degeneration
Treatment of Neovascular AMD: Artificial Intelligence in Real-world Setting
The purpose of this study is to implement quantitative assessment tools for the treatment of active neovascular AMD patients in a real-world setting in order to provide advantages for both patients (treatment burden) and…
- Trial name
- NCT05093374
- Testing
- anti-VEGF agent
- Where
- Austria
- Volunteers
- 290 people
- Sponsor
- Medical University of Vienna
Age-Related Macular Degeneration
Visual Function Change in Wet Age-related Macular Degeneration Patients With Better Baseline Visual Acuity
Although the number of wet AMD patients with the better visual acuity is increasing, the visual improvement in patients with the better vision may not be so significant after anti-vascular endothelial growth factor (VEGF)…
- Trial name
- NCT06330220
- Testing
- Aflibercept Injection [Eylea]
- Where
- South Korea
- Volunteers
- 12 people
- Sponsor
- Seoul National University Hospital
Wet Age-related Macular Degeneration
First in Human Study to Evaluate the Safety and Tolerability of EYP-1901 in Patients With Wet Age Related Macular Degeneration (wAMD)
Phase 1 open-label study to assess the bioactivity, ocular and systemic safety, tolerability, and pharmacokinetics of a single dose injections of EYP-1901 at three dose levels: 440 µg, 2060 µg and 3090 µg in subjects with Wet Age…
- Trial name
- NCT04747197
- Testing
- EYP-1901
- Where
- 11 sites in United States
- Volunteers
- 17 people
- Sponsor
- EyePoint Pharmaceuticals, Inc.
Macular Degeneration
Study of Intravitreal Microplasmin in Relieving Vitreo-Macular Adhesion in Neovascular Age-related Macular Degeneration
The purpose of this study is to determine whether microplasmin given by intravitreal injection is effective and safe for the treatment of wet age-related macular degeneration (AMD) in patients who have focal vitreomacular…
- Trial name
- AMD (NCT00996684)
- Testing
- Microplasmin
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- University of California, Los Angeles